Bellicum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BLCM)

$7.03 +0.36 (+5.40 %)
(As of 02/25/2018 03:08 AM ET)
Previous Close$7.03
Today's Range$6.79 - $7.53
52-Week Range$5.02 - $15.55
Volume1.32 million shs
Average Volume1.15 million shs
Market Capitalization$246.40 million
P/E Ratio-2.35
Dividend YieldN/A
Beta0.7

About Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BLCM
CUSIPN/A
Phone+1-832-3841100

Debt

Debt-to-Equity Ratio0.23%
Current Ratio6.08%
Quick Ratio6.08%

Price-To-Earnings

Trailing P/E Ratio-2.35117056856187
Forward P/E Ratio-2.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$390,000.00
Price / Sales599.53
Cash FlowN/A
Price / CashN/A
Book Value$3.56 per share
Price / Book1.97

Profitability

Trailing EPS($2.99)
Net Income$-69,240,000.00
Net MarginsN/A
Return on Equity-77.16%
Return on Assets-56.45%

Miscellaneous

Employees110
Outstanding Shares33,260,000

Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.03. The biopharmaceutical company earned $0.13 million during the quarter, compared to analyst estimates of $0.03 million. The firm's revenue for the quarter was up 18.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.66) EPS. View Bellicum Pharmaceuticals' Earnings History.

Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2018?

7 brokerages have issued 1 year price objectives for Bellicum Pharmaceuticals' stock. Their predictions range from $6.00 to $31.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Bellicum Pharmaceuticals.

What are Wall Street analysts saying about Bellicum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Complex Cases. The three cases of encephalopathy occurred in three patients, certain of whom had failed prior transplantation, have a history of immunodeficiency, infection, and/or treatment with rimiducid and other medications. To-date, Bellicum has treated over 240 patients with allogeneic haploidentical transplants with limited rates of transplant-related mortality. This compares to historical studies of allogeneic transplantation by the Center for International Blood & Marrow Transplant Research that have demonstrated that more than a third of deaths occur from occurrences of GvHD and infection, which BPX-501 is aimed at addressing. That being said, we are not yet clear on the relationship of these encephalopathy events to BPX-501 treatment, which lowers our overall confidence in the BPX-501 program." (1/31/2018)
  • 2. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (1/22/2018)
  • 3. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)

Who are some of Bellicum Pharmaceuticals' key competitors?

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the folowing people:

  • James Farrell Brown, Independent Chairman of the Board (Age 52)
  • Richard A. Fair, President, Chief Executive Officer, Director (Age 48)
  • David M Spencer Ph.D., Founder, Chief Scientific Officer (Age 54)
  • Kevin M. Slawin M.D., Founder (Age 55)
  • Alan A. Musso CPA, Chief Financial Officer, Treasurer (Age 55)
  • Ken Moseley J.D., Senior Vice President, General Counsel, Corporate Secretary (Age 60)
  • William Grossman M.D., Ph.D, Chief Medical Officer
  • James M. Daly, Independent Director (Age 55)
  • Stephen R. Davis, Independent Director (Age 56)
  • Reid M. Huber Ph.D., Independent Director (Age 45)

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Who owns Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.96%), Prosight Management LP (0.91%), Vident Investment Advisory LLC (0.45%), Goldman Sachs Group Inc. (0.45%), Millennium Management LLC (0.37%) and Deutsche Bank AG (0.33%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley and Kevin M Slawin. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Who sold Bellicum Pharmaceuticals stock? Who is selling Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schwab Charles Investment Management Inc., Berson & Corrado Investment Advisors LLC, Bank of New York Mellon Corp, Raymond James & Associates, Mcdaniel Terry & Co. and Wells Fargo & Company MN. Company insiders that have sold Bellicum Pharmaceuticals company stock in the last year include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer and Ken Moseley. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Who bought Bellicum Pharmaceuticals stock? Who is buying Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Millennium Management LLC, X Square Capital LLC, Virtus Fund Advisers LLC, Vident Investment Advisory LLC, Virtu Financial LLC, Franklin Street Advisors Inc. NC and Ellington Management Group LLC. View Insider Buying and Selling for Bellicum Pharmaceuticals.

How do I buy Bellicum Pharmaceuticals stock?

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $7.03.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $246.40 million and generates $390,000.00 in revenue each year. The biopharmaceutical company earns $-69,240,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Bellicum Pharmaceuticals employs 110 workers across the globe.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 W Holcombe Blvd Ste 800, HOUSTON, TX 77030-3307, United States. The biopharmaceutical company can be reached via phone at +1-832-3841100 or via email at [email protected]


MarketBeat Community Rating for Bellicum Pharmaceuticals (BLCM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  364
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bellicum Pharmaceuticals (NASDAQ:BLCM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.713.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$26.20$26.20$26.20
Price Target Upside: 169.87% upside186.03% upside155.36% upside210.61% upside

Bellicum Pharmaceuticals (NASDAQ:BLCM) Consensus Price Target History

Price Target History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals (NASDAQ:BLCM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Cantor FitzgeraldSet Price TargetBuy$10.00HighView Rating Details
2/16/2018CitigroupBoost Price TargetBuy -> Hold$24.00 -> $27.00HighView Rating Details
1/31/2018SunTrust BanksLower Price TargetHold -> Buy$18.00HighView Rating Details
1/31/2018Wells Fargo & CoDowngradeOutperform -> Market Perform$6.00HighView Rating Details
12/12/2017Raymond James FinancialReiterated RatingBuyHighView Rating Details
9/14/2017Jefferies GroupReiterated RatingBuy$16.00LowView Rating Details
6/24/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$31.00LowView Rating Details
8/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $31.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Bellicum Pharmaceuticals (NASDAQ:BLCM) Earnings History and Estimates Chart

Earnings by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals (NASDAQ BLCM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.74)($0.71)$0.03 million$0.13 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.65)($0.74)$0.08 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.70)($0.80)$0.09 million$0.13 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.71)($0.74)$0.10 million$0.08 millionViewN/AView Earnings Details
11/9/2016Q3($0.63)($0.66)$0.09 million$0.11 millionViewN/AView Earnings Details
8/8/2016Q216($0.57)($0.61)$0.10 million$0.10 millionViewListenView Earnings Details
5/9/2016Q1 2016($0.51)($0.56)$0.50 million$0.09 millionViewN/AView Earnings Details
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details
5/11/2015Q1($0.22)($0.30)$0.50 million$0.11 millionViewN/AView Earnings Details
3/11/2015Q4($11.79)($2.02)$0.60 million$0.02 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bellicum Pharmaceuticals (NASDAQ:BLCM) Earnings Estimates

2018 EPS Consensus Estimate: ($3.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.80)($0.80)($0.80)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181($0.87)($0.87)($0.87)
Q4 20181($0.80)($0.80)($0.80)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bellicum Pharmaceuticals (NASDAQ BLCM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.77%
Institutional Ownership Percentage: 56.20%
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals (NASDAQ BLCM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018Bros. Advisors Lp BakerMajor ShareholderSell880,735$8.20$7,222,027.00View SEC Filing  
1/17/2018Bros. Advisors Lp BakerMajor ShareholderSell260,600$8.63$2,248,978.00View SEC Filing  
1/9/2018Alan K SmithEVPSell487$9.40$4,577.802,087View SEC Filing  
12/11/2017Alan A MussoCFOSell17,117$9.33$159,701.6131,585View SEC Filing  
11/27/2017Alan A MussoCFOSell6,206$9.89$61,377.34View SEC Filing  
7/24/2017Alan K. SmithEVPSell437$11.85$5,178.45View SEC Filing  
7/13/2017Ken MoseleyVPSell13,823$12.26$169,469.9814,314View SEC Filing  
7/10/2017David M. SpencerInsiderSell10,000$11.54$115,400.00View SEC Filing  
5/25/2017Alan A. MussoCFOSell6,311$12.24$77,246.64View SEC Filing  
3/24/2017Bros. Advisors Lp BakerMajor ShareholderBuy166,666$12.00$1,999,992.00View SEC Filing  
2/7/2017Kevin M SlawinDirectorSell30,000$12.54$376,200.0084,206View SEC Filing  
12/15/2016Kevin M SlawinInsiderSell30,000$15.45$463,500.0084,206View SEC Filing  
12/5/2016David M SpencerInsiderSell5,000$20.00$100,000.00146,082View SEC Filing  
12/1/2016Annemarie MoseleyCOOSell25,000$17.54$438,500.00View SEC Filing  
11/28/2016Alan A. MussoCFOSell29,300$19.51$571,643.00View SEC Filing  
9/23/2016Ken MoseleyVPSell11,800$20.10$237,180.00444View SEC Filing  
9/23/2016Kevin M SlawinInsiderSell23,416$20.12$471,129.9295,464View SEC Filing  
9/20/2016David M SpencerInsiderSell2,500$20.01$50,025.00173,382View SEC Filing  
9/20/2016Ken MoseleyVPSell2,200$20.01$44,022.001,044View SEC Filing  
8/15/2016Ken MoseleyVPSell1,000$20.00$20,000.00View SEC Filing  
8/15/2016Kevin M SlawinInsiderSell67,000$19.31$1,293,770.00100,079View SEC Filing  
7/27/2016David M. SpencerInsiderSell10,000$15.00$150,000.00View SEC Filing  
7/18/2016Kevin M SlawinCTOSell2,719$13.99$38,038.81134,206View SEC Filing  
7/15/2016Kevin M SlawinCTOSell22,281$13.72$305,695.32136,925View SEC Filing  
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.0018,486View SEC Filing  
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.0015,196View SEC Filing  
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00159,206View SEC Filing  
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00251View SEC Filing  
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00178,600View SEC Filing  
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.0088,742View SEC Filing  
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.0097View SEC Filing  
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.0063,862View SEC Filing  
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00178,600View SEC Filing  
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.0066,362View SEC Filing  
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bellicum Pharmaceuticals (NASDAQ BLCM) News Headlines

Source:
DateHeadline
Bellicum Pharmaceuticals Inc (BLCM) Expected to Announce Quarterly Sales of $80,000.00Bellicum Pharmaceuticals Inc (BLCM) Expected to Announce Quarterly Sales of $80,000.00
www.americanbankingnews.com - February 23 at 3:08 PM
Cantor Fitzgerald Reiterates "$10.00" Price Target for Bellicum Pharmaceuticals (BLCM)Cantor Fitzgerald Reiterates "$10.00" Price Target for Bellicum Pharmaceuticals (BLCM)
www.americanbankingnews.com - February 23 at 9:12 AM
Bellicum Pharma (BLCM) Reports Update on Clinical Hold of US BPX-501 Studies - StreetInsider.comBellicum Pharma (BLCM) Reports Update on Clinical Hold of US BPX-501 Studies - StreetInsider.com
www.streetinsider.com - February 23 at 8:16 AM
Bellicum Announces Update on Clinical Hold of U.S. BPX-501 StudiesBellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies
finance.yahoo.com - February 23 at 8:16 AM
Bellicum Pharma (BLCM) Names Edmund P. Harrigan MD to Board - StreetInsider.comBellicum Pharma (BLCM) Names Edmund P. Harrigan MD to Board - StreetInsider.com
www.streetinsider.com - February 22 at 8:15 AM
IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF ... - GlobeNewswire (press release)IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF ... - GlobeNewswire (press release)
globenewswire.com - February 21 at 8:16 AM
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, MD to its Board of Directors - GlobeNewswire (press release)Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, MD to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 21 at 8:16 AM
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of DirectorsBellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors
finance.yahoo.com - February 21 at 8:16 AM
IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc.IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 20 at 5:50 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - February 20 at 5:50 PM
Pomerantz Law Firm Announces the Filing of a Class Action against ... - PR Newswire (press release)Pomerantz Law Firm Announces the Filing of a Class Action against ... - PR Newswire (press release)
www.prnewswire.com - February 18 at 8:14 AM
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 17 at 5:02 PM
Bellicum Pharmaceuticals (BLCM) Given New $27.00 Price Target at CitigroupBellicum Pharmaceuticals (BLCM) Given New $27.00 Price Target at Citigroup
www.americanbankingnews.com - February 17 at 12:10 AM
BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCMBLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCM
finance.yahoo.com - February 15 at 5:24 PM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCMSHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM
finance.yahoo.com - February 13 at 3:40 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline – April 9, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline – April 9, 2018
finance.yahoo.com - February 13 at 3:40 PM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 12 at 3:41 PM
Is Bellicum Pharmaceuticals, Inc. a Buy Now?Is Bellicum Pharmaceuticals, Inc. a Buy Now?
finance.yahoo.com - February 10 at 3:41 PM
Pomerantz LLP: Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCMPomerantz LLP: Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
www.finanznachrichten.de - February 10 at 9:10 AM
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCMPomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
finance.yahoo.com - February 10 at 9:10 AM
Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 9 at 3:50 PM
Ongoing Investigation: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.Ongoing Investigation: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 9 at 9:14 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - February 8 at 3:39 PM
Heres how Triad stocks fared this weekHere's how Triad stocks fared this week
finance.yahoo.com - February 8 at 3:39 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018
finance.yahoo.com - February 8 at 8:08 AM
The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 8 at 8:08 AM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bellicum Pharmaceuticals, Inc.IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - February 7 at 8:51 AM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCMEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM
finance.yahoo.com - February 6 at 3:39 PM
Bellicum Pharmaceuticals Inc (BLCM) Receives Consensus Rating of "Hold" from BrokeragesBellicum Pharmaceuticals Inc (BLCM) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 6 at 10:40 AM
Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical OfficerBellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer
finance.yahoo.com - February 5 at 8:58 AM
Zacks: Analysts Expect Bellicum Pharmaceuticals Inc (BLCM) Will Post Earnings of -$0.69 Per ShareZacks: Analysts Expect Bellicum Pharmaceuticals Inc (BLCM) Will Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - February 4 at 1:16 AM
Investors Purchase Large Volume of Bellicum Pharmaceuticals Call Options (BLCM)Investors Purchase Large Volume of Bellicum Pharmaceuticals Call Options (BLCM)
www.americanbankingnews.com - February 3 at 1:24 AM
SunTrust Banks Weighs in on Bellicum Pharmaceuticals Incs FY2018 Earnings (BLCM)SunTrust Banks Weighs in on Bellicum Pharmaceuticals Inc's FY2018 Earnings (BLCM)
www.americanbankingnews.com - February 2 at 1:25 PM
Brokers Set Expectations for Bellicum Pharmaceuticals Incs FY2022 Earnings (BLCM)Brokers Set Expectations for Bellicum Pharmaceuticals Inc's FY2022 Earnings (BLCM)
www.americanbankingnews.com - February 1 at 4:22 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc. - BLCMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc. - BLCM
finance.yahoo.com - January 31 at 3:39 PM
SunTrust Banks Cuts Bellicum Pharmaceuticals (BLCM) Price Target to $18.00SunTrust Banks Cuts Bellicum Pharmaceuticals (BLCM) Price Target to $18.00
www.americanbankingnews.com - January 31 at 12:45 PM
Bellicum Pharma (BLCM) Says Studies of BPX-501 Placed on Clinical Hold Following Three Cases of EncephalopathyBellicum Pharma (BLCM) Says Studies of BPX-501 Placed on Clinical Hold Following Three Cases of Encephalopathy
www.streetinsider.com - January 31 at 9:10 AM
Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United StatesBellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
finance.yahoo.com - January 31 at 9:10 AM
Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Corcept TherapeuticsToday’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Corcept Therapeutics
finance.yahoo.com - January 31 at 9:10 AM
Will 2018 Be Bellicum Pharmaceuticals, Inc.s Best Year Yet? - Motley FoolWill 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet? - Motley Fool
www.fool.com - January 27 at 3:42 PM
Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?
finance.yahoo.com - January 25 at 3:40 PM
Will 2018 Be Bellicum Pharmaceuticals, Inc.s Best Year Yet?Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?
www.fool.com - January 25 at 11:07 AM
Bellicum Pharmaceuticals (BLCM) Stock Rating Lowered by Zacks Investment ResearchBellicum Pharmaceuticals (BLCM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 22 at 6:36 PM
$80,000.00 in Sales Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter$80,000.00 in Sales Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - January 20 at 2:58 PM
Bellicum Pharmaceuticals, Inc. (BLCM) Major Shareholder Sells $2,248,978.00 in StockBellicum Pharmaceuticals, Inc. (BLCM) Major Shareholder Sells $2,248,978.00 in Stock
www.americanbankingnews.com - January 19 at 9:32 PM
Bellicum Pharmaceuticals, Inc. (BLCM) Major Shareholder Sells $7,222,027.00 in StockBellicum Pharmaceuticals, Inc. (BLCM) Major Shareholder Sells $7,222,027.00 in Stock
www.americanbankingnews.com - January 19 at 9:32 PM
Bellicum Pharmaceuticals (BLCM) Upgraded at Zacks Investment ResearchBellicum Pharmaceuticals (BLCM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 19 at 7:26 PM
Zacks Investment Research Downgrades Bellicum Pharmaceuticals (BLCM) to HoldZacks Investment Research Downgrades Bellicum Pharmaceuticals (BLCM) to Hold
www.americanbankingnews.com - January 12 at 5:54 PM
Bellicum Pharmaceuticals, Inc. (BLCM) Receives Average Recommendation of "Buy" from AnalystsBellicum Pharmaceuticals, Inc. (BLCM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 12 at 8:02 AM
Bellicum Pharmaceuticals (BLCM) Stock Rating Upgraded by Zacks Investment ResearchBellicum Pharmaceuticals (BLCM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 10 at 6:00 PM

SEC Filings

Bellicum Pharmaceuticals (NASDAQ:BLCM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bellicum Pharmaceuticals (NASDAQ:BLCM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bellicum Pharmaceuticals (NASDAQ BLCM) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.